INFO & CONTACTS:  +39 02 2390 1

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers

Phase: Phase I-II clinical trials

Principal Investigator: Dott. Pietrantonio Filippo

Main Facility: Oncologia Medica Gastroenterologica

Drug: HER3-DXd=patritumab deruxtecan

Pathologies: Intestinal cancer

ClinicalTrials.gov: Read the details about clinical trials

This is a Phase 1/2, non-randomized, multicenter, open-label study evaluating HER3-DXd monotherapy in patients with selected metastatic GI cancers. Three initial cohorts with high unmet medical need in the refractory setting will be studied: colorectal cancer (CRC), biliary tract cancer (BTC), and hepatocellular carcinoma (HCC). These tumors were chosen due to the high need for effective treatments and the expected benefit/risk balance of HER3-DXd in these populations.

Approximately 130 eligible participants will be randomly distributed into the following cohorts:

• Cohort 1: 2L CRC (approximately 40 participants)

• Cohort 2: 2L+ BTC (approximately 40 participants)

• Cohort 3: 2L HCC (up to approximately 50 participants, including the dose-escalation phase)

• Cohort 4: 2L GA (up to approximately 50 participants)

The primary objectives of the study are:

• Evaluate the objective response rate (ORR) according to RECIST 1.1, assessed by BICR.

• Evaluate the safety and tolerability of HER3-DXd, with monitoring for adverse events (AEs) and serious adverse events (SAEs), and discontinuation of the intervention for AEs.

Last update: 16/07/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe